Bradycardia News and Research

RSS

Bradycardia, ("heart slowness"), as applied to adult medicine, is defined as a resting heart rate of under 60 beats per minute, though it is seldom symptomatic until the rate drops below 50 beat/min.

Discovery Labs reports data from SURFAXIN preclinical study on RDS

Discovery Laboratories, Inc., a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, reported that data from a preclinical study of SURFAXIN LS (lyophilized KL4 surfactant) was recently published in the May issue of Pediatric Research.

10 May 2012

Lower rate of reintubation observed in infants receiving SURFAXIN

Discovery Laboratories, Inc. today announced the presentation of a new pharmacoeconomic analysis demonstrating that the lower rate of reintubation previously reported in infants treated with SURFAXIN, when compared with infants treated with Curosurf® and Survanta®, the current global market leading surfactants, also resulted in a potential hospital cost savings of $160,000 to $252,000 per 100 infants.

2 May 2012

Boston Scientific receives European CE Mark approval for INGENIO family of pacemakers

Boston Scientific Corporation announces CE Mark approval and European market launch of its INGENIO and ADVANTIO pacemakers and INVIVE cardiac resynchronization therapy pacemakers.

11 Apr 2012

Medtronic pacemaker reduces risk of syncope recurrence

Medtronic, Inc. today announced the results of a double-blind, randomized study, ISSUE-3, which found that patients who suffered from fainting due to neurocardiogenic syncope had fewer fainting occurrences when treated with a Medtronic pacemaker.

From Medtronic 27 Mar 2012

Exposure to MSS could help reduce cardiorespiratory events in preterm infants

When babies are born prematurely, they are thrust into a hospital environment that while highly successful at saving their lives, is not exactly the same as the mother's womb where ideal development occurs. The Neonatal Intensive Care Unit (NICU) is equipped with highly skilled care givers and incubators that regulate temperature and humidity, but Amir Lahav, ScD, PhD, director of the Neonatal Research Lab at Brigham and Women's Hospital (BWH) thought that something was missing - simulation of the maternal sounds that a baby would hear in the womb.

8 Mar 2012

FDA approves Discovery Labs' SURFAXIN to prevent Respiratory Distress Syndrome

Discovery Laboratories, Inc., a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced that the United States Food and Drug Administration (FDA) has approved SURFAXIN (lucinactant) for the prevention of Respiratory Distress Syndrome (RDS) in premature infants at high risk for RDS.

6 Mar 2012

Human Genome Sciences to present abstracts regarding BENLYSTA, SLE at ACR/ARHP meeting

Human Genome Sciences, Inc. announced today that several abstracts related to BENLYSTA (belimumab) and systemic lupus erythematosus will be presented at the annual meeting of the American College of Rheumatology/ Association of Rheumatology Health Professionals, being held in Chicago, IL from November 4 to November 9, 2011.

5 Nov 2011

Research reveals significant increase in infections associated with cardiac electrophysiological devices

New research from the Jefferson Heart Institute shows that patients in the United States who receive cardiac electrophysiological devices (CIEDs), including permanent pacemakers and implantable cardioverter-defibrillators (ICDs) are now at greater risk of contracting an infection over the life span of the device.

23 Aug 2011

Merck secures worldwide rights to vernakalant i.v.

Merck, known as MSD outside the United States and Canada, and Astellas US LLC, the U.S. subsidiary of Astellas Pharma Inc. today announced that they have entered into an agreement under which Merck, through a subsidiary, will acquire the exclusive rights to develop and commercialize the investigational intravenous formulation of vernakalant (vernakalant i.v.) in Canada, Mexico and the United States from Astellas.

27 Jul 2011

Daiichi Sankyo, Regency Therapeutics launch SPRIX Nasal Spray for severe pain

Regency Therapeutics, a newly established division of Luitpold Pharmaceuticals, Inc., and its co-promotion partner Daiichi Sankyo, Inc., announced today that they have launched SPRIX® (ketorolac tromethamine) Nasal Spray and that it is now commercially available.

17 May 2011

Lead investigator to discuss growing impact of AFib on US health care costs and resources

Two studies to be presented this week address the often-overlooked costs associated with atrial fibrillation, the most common form of cardiac arrhythmia.

5 May 2011

Baxter enters definitive agreement to acquire Prism

Baxter International Inc. announced today that it has entered into a definitive agreement to acquire privately-held Prism Pharmaceuticals, Inc., a specialty pharmaceutical company based in King of Prussia, PA. Prism Pharmaceuticals has developed and received U.S. Food and Drug Administration (FDA) approval for multiple presentations of NEXTERONE® (amiodarone HCl), an antiarrhythmic agent.

From Baxter International Inc. 18 Apr 2011

St. Jude Medical's Accent MRI pacemaker and Tendril MRI lead system receives European CE Mark approval

St. Jude Medical, Inc., a global medical device company, today announced that it has received European CE Mark approval for its Accent MRI™ pacemaker and Tendril MRI™ lead. The system, designed and tested for safe use in a Magnetic Resonance Imaging (MRI) environment and approved as MR-Conditional, allows patients to undergo full-body, high-resolution MRI scans.

18 Apr 2011

Baxter's ARTISS phase III study results in face lift surgery presented at AAPS meeting

Baxter International Inc. announced today the results of a phase III study evaluating the safety and efficacy of ARTISS in 75 patients.

From Baxter International Inc. 12 Apr 2011

First MRI-compatible pacemaker implanted in patient at MetroSouth Medical Center

Lee Ryan, 74, a Worth, Illinois man was among the first in Chicago to receive a MRI-compatible pacemaker. His pacemaker was implanted at MetroSouth Medical Center, a hospital known for its excellent cardiac care.

24 Mar 2011

FDA approves BENLYSTA for active, autoantibody-positive systemic lupus erythematosus

Human Genome Sciences, Inc. and GlaxoSmithKline PLC today announced that the U.S. Food and Drug Administration has approved BENLYSTA® (belimumab) for the treatment of adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) who are receiving standard therapy.

10 Mar 2011

UCH installs GE's CARESCAPE Monitor B850 to enhance clinical decision making in the NICU

GE Healthcare today announced that the University of Colorado Hospital (UCH) has installed the new CARESCAPE™ Monitor B850, the company's latest advance in bedside patient monitoring, to help enhance clinical decision making in the Neonatal Intensive Care Unit (NICU). Deployed in UCH's 50-bed NICU and Neonatal OR, the CARESCAPE Monitor B850 enables access to critical patient information from any bedside monitor anywhere in the unit.

28 Feb 2011

'Pacemaker' Hcn4 gene responsible for generation of repetitive activity in SAN tissue and heart rate regulation

The study of Dario DiFrancesco and his equipe identifies the "pacemaker" Hcn4 gene as the gene functionally responsible for the generation of repetitive activity in sinoatrial node tissue and for the regulation of heart rate. Hcn4 codes for HCN4 channels, the molecular components of "funny" ion channels of pacemaker cells of the sinoatrial node (SAN) tissue.

14 Jan 2011

Shionogi brings KAPVAY ADHD drug to the U.S market

Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced a true milestone as it marks the first commercial availability for the non-central nervous system stimulant medication KAPVAY™, an extended-release oral formulation of clonidine for Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents.

10 Jan 2011

Sunovion reports results of Latuda third phase 3 worldwide clinical trial for schizophrenia

Sunovion Pharmaceuticals Inc. today announced the results of the PEARL 3 study, the third phase 3 worldwide clinical trial of Latuda® (lurasidone HCl) tablets, a once-daily atypical antipsychotic agent recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with schizophrenia. In this six-week, placebo-controlled trial, both fixed doses of LATUDA 80 and 160 mg once-daily, demonstrated statistically significant improvement in symptoms of schizophrenia versus placebo across both primary and secondary efficacy measures.

9 Dec 2010